Table 1.
Baseline characteristics.
| Median (IQR) or n (%) | |
|---|---|
| Patient sex | |
| male | 91 (48.9%) |
| female | 95 (51.1%) |
| Patient age (years) | 60 (51–65) |
| SAF (AU) | 2.3 (1.9–2.6) |
| Body mass index (kg/m2) | 26.4 (23.5–30.1) |
| HBV | 18 (9.7%) |
| HCV | 7 (3.8%) |
| Chemotherapy | 86 (46.2%) |
| Diabetes | 24 (12.9%) |
| Arterial hypertension | 63 (33.9%) |
| Smokers | 84/181 (46.4%) |
| Cirrhosis | 7 (3.8%) |
| Liver fibrosis | 49/174 (28.2%) |
| Macrovesicular steatosis ≥ 10% | 54/155 (34.8%) |
| Macrovesicular steatosis ≥ 20% | 26/155 (16.8%) |
| Macrovesicular steatosis ≥ 30% | 18/155 (11.6%) |
| Preoperative laboratory tests | |
| white blood count (103/mm3) | 6.3 (5.3–7.8) |
| hemoglobin (g/dL) | 13.5 (12.6–14.2) |
| platelets (103/mm3) | 222 (181–263) |
| creatinine (mg/dL) | 0.8 (0.7–0.9) |
| bilirubin (mg/dL) | 0.5 (0.4–0.7) |
| INR | 1.0 (1.0–1.1) |
| albumin (g/dL) | 4.4 (4.1–4.6) |
| AST (U/L) | 28 (23–39) |
| ALT (U/L) | 27 (20–41) |
| Primary diagnosis | |
| colorectal liver metastases | 81 (43.6%) |
| hepatocellular cancer | 22 (11.8%) |
| gallbladder cancer | 17 (9.1%) |
| cholangiocarcinoma | 19 (10.2%) |
| other | 47 (25.3%) |
IQR, interquartile range; SAF, skin autofluorescence; AU, arbitrary unit; INR, international normalized ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase.